Table 1.
Demographic and clinical data of the cohort of 50 patients with cSCC with (cohorts PRI+, MET) or without lymph node metastasis (PRI-).
| Variable | PRI+/MET (metastasizing tumors), n = 29 | PRI- (locally confined tumors), n = 21 | Total (n = 50) | p-value |
|---|---|---|---|---|
| Mean age, years (range) | 74.8 (32 to 93) | 68.2 (39 to 92) | 72.1 (32 to 93) | 0.034 c |
| Sex, n (%) | ||||
| Female | 2 (7) | 4 (19) | 6 (12) | 0.22 d |
| Male | 27 (93) | 17 (81) | 44 (88) | |
| Site of primary tumor, n (%) | ||||
| Scalp | 4 (14) | 5 (24) | 9 (18) | 0.99e e |
| Ear and temple | 5 (17) | 7 (33) | 12 (24) | |
| Nose and midface | 3 (10) | 5 (24) | 8 (16) | |
| Lip | 2 (7) | 2 (10) | 4 (8) | |
| Neck | 1 (3) | 2 (10) | 3 (6) | |
| Unknown | 14 (48) | 0 | 14 (28) | |
| Recurrent tumor, n (%) a | ||||
| No | 15 (52) | 15 (71) | 30 (60) | 0.24 d |
| Yes | 14 (48) | 6 (29) | 20 (40) | |
| T-stage at surgery, n (%) b | ||||
| 0 or unknown | 12 (41) | 1 (5) | 13 (26) | 0.039 e |
| 1 | 3 (10) | 3 (14) | 6 (12) | |
| 2 | 6 (21) | 4 (19) | 10 (20) | |
| 3 | 6 (21) | 11 (52) | 17 (34) | |
| 4 | 2 (7) | 2 (10) | 4 (8) | |
| N-stage at surgery, n (%) b | ||||
| 0 | 5 (17) | 21 (100) | 26 (52) | <0.001 e |
| 1 | 5 (17) | 0 | 5 (10) | |
| 2 | 4 (14) | 0 | 4 (8) | |
| 3 | 13 (45) | 0 | 13 (26) | |
| Unknown | 2 (7) | 0 | 2 (4) | |
| Overall stage (AJCC 7th edition) b | ||||
| I | 1 (3) | 3 (14) | 4 (8) | <0.001 e |
| II | 2 (7) | 4 (19) | 6 (12) | |
| III | 5 (17) | 11 (52) | 16 (32) | |
| IV | 20 (69) | 2 (10) | 22 (44) | |
| Unknown | 1 (3) | 1 (3) | 2 (4) | |
| Histopathological grading, n (%) b | ||||
| 1 (well differentiated) | 2 (7) | 2 (10) | 4 (8) | 0.13 e |
| 2 (moderately differentiated) | 13 (45) | 14 (67) | 27 (54) | |
| 3 (poorly differentiated) | 14 (48) | 4 (19) | 18 (36) | |
| Unknown | 0 | 1 (5) | 1 (2) | |
| Lymph-vascular infiltration (LVI), n (%) b | ||||
| No | 18 (62) | 18 (86) | 36 (72) | 0.11 d |
| Yes | 10 (34) | 3 (14) | 13 (26) | |
| Unknown | 1 (3) | 0 | 1 (2) | |
| Perineural invasion (PNI), n (%) b | ||||
| No | 11 (38) | 11 (52) | 22 (44) | 0.56 d |
| Yes | 15 (52) | 10 (48) | 25 (50) | |
| Unknown | 3 (10) | 0 | 3 (6) | |
a
Recurrent tumors at surgery. Recurrences after last surgery are not included.
b
When multiple samples of a single patient from the primary (PRI+) and lymph node metastasis (MET) were analyzed, the index tumor (PRI+) was prioritized.
c
Mann–Whitney U test.
d
Fisher exact test.
e
Chi-square test.